These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

570 related articles for article (PubMed ID: 25291139)

  • 21. Diversity of faecal oxalate-degrading bacteria in black and white South African study groups: insights into understanding the rarity of urolithiasis in the black group.
    Magwira CA; Kullin B; Lewandowski S; Rodgers A; Reid SJ; Abratt VR
    J Appl Microbiol; 2012 Aug; 113(2):418-28. PubMed ID: 22616725
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bifidobacterium animalis subsp. lactis decreases urinary oxalate excretion in a mouse model of primary hyperoxaluria.
    Klimesova K; Whittamore JM; Hatch M
    Urolithiasis; 2015 Apr; 43(2):107-17. PubMed ID: 25269440
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic effects of probiotics and herbal medications on oxalate nephrolithiasis: a mini systematic review.
    Taheri H; Feizabadi MM; Keikha R; Afkari R
    Iran J Microbiol; 2024 Feb; 16(1):4-18. PubMed ID: 38682062
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Probiotics for prevention of urinary stones.
    Lieske JC
    Ann Transl Med; 2017 Jan; 5(2):29. PubMed ID: 28217694
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oxalate metabolism in renal stone disease with special reference to calcium metabolism and intestinal absorption.
    Lindsjö M
    Scand J Urol Nephrol Suppl; 1989; 119():1-53. PubMed ID: 2669121
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Direct correlation between hyperoxaluria/oxalate stone disease and the absence of the gastrointestinal tract-dwelling bacterium Oxalobacter formigenes: possible prevention by gut recolonization or enzyme replacement therapy.
    Sidhu H; Schmidt ME; Cornelius JG; Thamilselvan S; Khan SR; Hesse A; Peck AB
    J Am Soc Nephrol; 1999 Nov; 10 Suppl 14():S334-40. PubMed ID: 10541258
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Oxalobacter formigenes--characteristics and role in development of calcium oxalate urolithiasis].
    Torzewska A
    Postepy Hig Med Dosw (Online); 2013 Nov; 67():1144-53. PubMed ID: 24379255
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of commercial kidney stone probiotic supplements.
    Ellis ML; Shaw KJ; Jackson SB; Daniel SL; Knight J
    Urology; 2015 Mar; 85(3):517-21. PubMed ID: 25733259
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oxalobacter formigenes: Opening the door to probiotic therapy for the treatment of hyperoxaluria.
    Jairath A; Parekh N; Otano N; Mishra S; Ganpule A; Sabnis R; Desai M
    Scand J Urol; 2015; 49(4):334-7. PubMed ID: 25645091
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of absence of intestinal oxalate degrading bacteria with urinary calcium oxalate stone formation.
    Mikami K; Akakura K; Takei K; Ueda T; Mizoguchi K; Noda M; Miyake M; Ito H
    Int J Urol; 2003 Jun; 10(6):293-6. PubMed ID: 12757596
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rapid reversal of hyperoxaluria in a rat model after probiotic administration of Oxalobacter formigenes.
    Sidhu H; Allison MJ; Chow JM; Clark A; Peck AB
    J Urol; 2001 Oct; 166(4):1487-91. PubMed ID: 11547118
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Applyed aspects of molecular biology of Bifidobacteria and Lactobacillus].
    Bondarenko VM
    Zh Mikrobiol Epidemiol Immunobiol; 2006; (2):89-97. PubMed ID: 16758909
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Simultaneous use of oxalate-degrading bacteria and herbal extract to reduce the urinary oxalate in a rat model: A new strategy.
    Afkari R; Feizabadi MM; Ansari-Moghadam A; Safari T; Bokaeian M
    Int Braz J Urol; 2019; 45(6):1249-1259. PubMed ID: 31808414
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oxalobacter sp. reduces urinary oxalate excretion by promoting enteric oxalate secretion.
    Hatch M; Cornelius J; Allison M; Sidhu H; Peck A; Freel RW
    Kidney Int; 2006 Feb; 69(4):691-8. PubMed ID: 16518326
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oxalate-Degrading Bacillus subtilis Mitigates Urolithiasis in a Drosophila melanogaster Model.
    Al KF; Daisley BA; Chanyi RM; Bjazevic J; Razvi H; Reid G; Burton JP
    mSphere; 2020 Sep; 5(5):. PubMed ID: 32907948
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of a probiotic to decrease enteric hyperoxaluria.
    Lieske JC; Goldfarb DS; De Simone C; Regnier C
    Kidney Int; 2005 Sep; 68(3):1244-9. PubMed ID: 16105057
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of Lactobacillus casei and Bifidobacterium breve on urinary oxalate excretion in nephrolithiasis patients.
    Ferraz RR; Marques NC; Froeder L; Menon VB; Siliano PR; Baxmann AC; Heilberg IP
    Urol Res; 2009 Apr; 37(2):95-100. PubMed ID: 19214493
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activity of probiotics from food origin for oxalate degradation.
    Soliman NR; Effat BAM; Mehanna NS; Tawfik NF; Ibrahim MK
    Arch Microbiol; 2021 Oct; 203(8):5017-5028. PubMed ID: 34282467
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Absorptive hyperoxaluria leads to an increased risk for urolithiasis or nephrocalcinosis in cystic fibrosis.
    Hoppe B; von Unruh GE; Blank G; Rietschel E; Sidhu H; Laube N; Hesse A
    Am J Kidney Dis; 2005 Sep; 46(3):440-5. PubMed ID: 16129205
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Forty Years of Oxalobacter formigenes, a Gutsy Oxalate-Degrading Specialist.
    Daniel SL; Moradi L; Paiste H; Wood KD; Assimos DG; Holmes RP; Nazzal L; Hatch M; Knight J
    Appl Environ Microbiol; 2021 Aug; 87(18):e0054421. PubMed ID: 34190610
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.